Open AccessComparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for <b><i>Helicobacter pylori</i></b>
Author(s) -
Teppei Adachi,
Shigenaga Matsui,
Tomohiro Watanabe,
Kazuki Okamoto,
Ayana Okamoto,
Masashi Kono,
Mitsunari Yamada,
Tatsuo Nagai,
Yoriaki Komeda,
Kosuke Minaga,
Ken Kamata,
Kentaro Yamao,
Mamoru Takenaka,
Yutaka Asakuma,
Toshiharu Sakurai,
Naoshi Nishida,
Hiroshi Kashida,
Masatoshi Kudo
Publication year - 2017
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000481224
Subject(s) - helicobacter pylori , clarithromycin , amoxicillin , metronidazole , esomeprazole , medicine , gastroenterology , group b , antibiotics , microbiology and biotechnology , biology
Clarithromycin (CAM)-based triple therapy comprising proton pump inhibitors and amoxicillin is administered as first-line eradication treatment against Helicobacter pylori infection. However, the eradication rate achieved with CAM-based triple therapy has decreased to <80% owing to the emergence of CAM-resistant strains. This prospective randomized study aimed to compare the efficacy of CAM-based and metronidazole (MNZ)-based triple therapy in terms of H. pylori eradication.